Evidence map›Paper›PMID 42164116›Full record

ArticleFrontiers in oncology2026

Alexandra Teixeira, João M Alves, Nuria Estévez-Gómez, Ângela Fernandes, Nuno Cerveira, Susana Bizarro, Manuel R Teixeira, Manuel Guerreiro, Isabel Castro, Belém Sampaio-Marques and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alexandra Teixeira *International Iberian Nanotechnology Laboratory (INL), Braga, Portugal.
João M Alves *Centro de Investigación en Nanomateriais e Biomedicina (CINBIO), Universidade de Vigo, Vigo, Spain.
Nuria Estévez-GómezCentro de Investigación en Nanomateriais e Biomedicina (CINBIO), Universidade de Vigo, Vigo, Spain.
Ângela FernandesLife and Health Sciences Research Institute (ICVS), Escola de Medicina, Universidade do Minho, Braga, Portugal.
Nuno CerveiraDepartment of Genetics, Portuguese Oncology Institute-Porto (IPO-Porto)/Porto Comprehensive Cancer Center, Porto, Portugal.
Susana BizarroDepartment of Genetics, Portuguese Oncology Institute-Porto (IPO-Porto)/Porto Comprehensive Cancer Center, Porto, Portugal.
Manuel R TeixeiraDepartment of Genetics, Portuguese Oncology Institute-Porto (IPO-Porto)/Porto Comprehensive Cancer Center, Porto, Portugal.
Manuel GuerreiroHospital da Arrábida, Vila Nova de Gaia, Portugal.
Isabel CastroLife and Health Sciences Research Institute (ICVS), Escola de Medicina, Universidade do Minho, Braga, Portugal.
Belém Sampaio-MarquesLife and Health Sciences Research Institute (ICVS), Escola de Medicina, Universidade do Minho, Braga, Portugal.
José MarizDepartment of Onco-hematology, Portuguese Oncology Institute-Porto (IPO-Porto), Porto, Portugal.
Sara Abalde-CelaInternational Iberian Nanotechnology Laboratory (INL), Braga, Portugal.
Lorena DiéguezInternational Iberian Nanotechnology Laboratory (INL), Braga, Portugal.
David PosadaCentro de Investigación en Nanomateriais e Biomedicina (CINBIO), Universidade de Vigo, Vigo, Spain.
Paula LudovicoLife and Health Sciences Research Institute (ICVS), Escola de Medicina, Universidade do Minho, Braga, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is the most frequent type of leukaemia in adults, often with poor outcomes due to the complex genetic landscape and low treatment efficacy. Autophagy, a conserved degradation process, plays an indispensable and context-dependent role in AML. This work explored the prognostic impact of autophagy-related genes compared to known AML-related genes. A two-gene signature (ATG16L1-OPTN) demonstrated that the expression of these autophagy-related genes correlates significantly with overall survival (OS). Cox regression analysis and validation in two larger cohorts (BEATAML2andTCGA LAML) confirmed the association of this signature with worst OS, reinforcing its clinical relevance. These results suggest the ATG16L1-OPTN signature as a novel and robust prognostic marker for predicting OS in AML patients.

Indexed as

acute myeloid leukemia (AML)ATG16L1autophagyOPTNoverall survival (OS)

Identifiers

PMID42164116
PMCPMC13184388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.